MRNA
MRNA Moderna Options Ahead of EarningsIf you haven`t sold MRNA at all time high:
Then analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 115usd strike price Calls with
an expiration date of 2024-7-19,
for a premium of approximately $8.00.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Moderna Breaks Out 12.68% For The First Time In A YearModerna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due to make its decision on Moderna's shot in less than two weeks. Moderna ( NASDAQ:MRNA ) hopes to launch its vaccine for older adults this fall. If approved, this would be Moderna's second commercial product behind its Covid vaccine.
Moderna's Covid vaccine sales plummeted nearly 91% to $167 million during the first quarter, but handily beat analysts' forecast for $93 million. The European Union plans to buy up to 36 million doses of its Covid vaccine each year for at least four years. The company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is available in time with the seasonal flu shot.
From a financial standpoint, Moderna ( NASDAQ:MRNA ) is retaining its outlook for the year. The company expects to notch $4 billion in sales of its respiratory vaccines. That will be weighted to the back half of the year with less than $300 million in sales projected for the first half of 2024. Moderna ( NASDAQ:MRNA ) stock analysts project $4.19 billion in full-year revenue, including $4.06 billion in sales from the company's products.
The RSV vaccine could be a big moneymaker for Moderna ( NASDAQ:MRNA ). Pfizer and GSK launched their RSV shots for older adults last year, with Abrysvo and Arexvy generating $145 million and $228 million in sales respectively. Moderna stock analysts already expect some sales of Moderna's product — $10 million in the June quarter, according to FactSet.
Moderna is ( NASDAQ:MRNA ) also planning to work with U.S. regulators on the timing of its next Covid vaccine. Officials will choose the next variant to target in booster shots on May 16, then it will be off to the races, so to speak, to run testing for Moderna's updated shot. Moderna's goal is to launch the Covid booster shot in timing with the fall flu vaccine campaign.
✏️ Weekly Report: Volatility makes Cash the King againGENERAL COMMENTS
Today, the Federal Reserve maintained its interest rates unchanged, highlighting the ongoing challenges in curbing inflation. Initially, this announcement propelled the markets upwards, but a sharp downturn occurred in the final hour, leading to a decline as the day concluded.
The erratic market behavior demonstrated today makes it increasingly challenging to maintain positions in momentum stocks, and the majority of this quarter's earnings reports have been underwhelming. This situation underscores the strategy that cash remains paramount, complemented by selective, quick trading opportunities, as depicted in the following charts.
I will begin tonight's chart analysis with the Nasdaq-100 (QQQ).
NASDAQ:QQQ
The Qs are forming a bearish formation. What is worrying is that this is below the 50D Simple Moving average. As trading is a probabilities game, we can conclude that this leads to probabilities being lower that we continue to the downside. However, the direction of the general market indexes are very well influenced by the fundmental story of the economy health.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NASDAQ:SMTC
SMTC is up $4 from the $33 Buy Point (alerted in previous versions of this idea - go and check. Believe and Follow). This peaked yesterday with about +20% profit since the alert last week. Of course the way I manage this is never to let this to turn into a loss. My general go to tool is to take half here.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NASDAQ:KLAC
KLAC fell back to $687 after missing earnings. This of course stopped me out - but at no loss, since I move stopped up to break-even.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NASDAQ:SMCI
The stock missed its earnings and suffered a severe reaction of a gap down and drop -20% on the intraday.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NASDAQ:NVDA
NVDA slashed below the 50D SMA and this stopped me out. Waiting and watching this TML during its base building period.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NYSE:GS
Up $7 from the $419 buy point with stop raised to $416 just in case.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NYSE:CRM
CRM is prone to go lower if the market continues falling. A break below $266.50 is great place to short.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NYSE:LLY
Gapped up on good earnings. The next technical buy point is $801 accommodated with heavy volume.
––––––––––––––––––––––––––––––––––––––––––––––––––––
NASDAQ:MRNA
Earnings are due out tomorrow. If earnings are good then zooming through the $116 on good volume is a great technical buy point
XBI the ETF for Biotechnology LONGBiotechnology is expected to be a hot subsector this year as healthcare recovered further from
the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for
diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend
with XBI pivoting to bullish back in early November. I add long positions when I see a dip
on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with
the first upper VWAP band line and then the 135-138 zone underneath the second upper line
shown in thin red on the chart. This ETF smooths out the volatility characteristic of some
of the smaller biotechnology firms making it safer albeit with lesser rewards expectations.
Positions in NVAX and MRNA are having a good start to the week and will reflect in a small
way in this ETF which has broad constituent stocks within its portfolio.
Moderna's Vaccine Spark Hope in Head and Neck Cancer TreatmentIn a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology research.
The vaccine, mRNA-4157, aims to train the immune system to identify and combat specific mutations present in cancer cells, representing a pioneering approach in personalized cancer therapy. Following its success in treating melanoma, the vaccine has now demonstrated positive responses in patients with head and neck squamous cell carcinoma, a challenging form of cancer.
Data presented at the American Association for Cancer Research Annual Meeting showcased the vaccine's efficacy when administered in combination with Merck's Keytruda. The study, involving 22 patients, revealed promising clinical responses, including instances of complete remission. Notably, the combination therapy not only triggered robust immune responses but also exhibited favorable safety profiles, marking a significant milestone in cancer immunotherapy.
Jefferies analyst Michael Yee lauded the results, highlighting the potential of Moderna's therapy platform to transcend melanoma and extend its benefits to other cancer types. The data underscore the transformative potential of mRNA-based vaccines in revolutionizing cancer treatment paradigms and offering new hope to patients grappling with advanced malignancies.
The positive outcome has bolstered investor confidence in Moderna ( NASDAQ:MRNA ), propelling its shares to a three-month high. This uptrend reflects renewed enthusiasm for the biotech firm's diverse pipeline, which includes groundbreaking vaccines targeting respiratory syncytial virus and other infectious diseases, alongside innovative cancer therapies.
Looking ahead, Moderna's collaboration with Merck signals a concerted effort to advance the development of cancer immunotherapies. The initiation of a Phase 3 trial targeting lung cancer underscores the commitment to translating promising preclinical data into clinically meaningful outcomes, to deliver transformative therapies to patients in need.
As Moderna ( NASDAQ:MRNA ) continues to pioneer the frontier of mRNA-based therapeutics, the recent success of its cancer vaccine heralds a new era in precision medicine. With further advancements and clinical validations, this innovative approach holds the potential to reshape the landscape of cancer treatment and offer renewed hope for patients battling this devastating disease.
Looking bearish soon on MRNA.🔉Sound on!🔉
Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
$MRNA Bearish to Bullish Reversal NASDAQ:MRNA Bearish to Bullish Reversal
A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a bullish phase. It could signify a potential turning point in market sentiment, with investors becoming more optimistic about the stock's future prospects. Traders often look for confirmation signals to validate this reversal, such as increased trading volume or positive fundamental developments in the company.
Moderna Surge as it Dives into Promising Cancer Vaccine TrialsModerna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be attributed to several key factors that are igniting investor enthusiasm and confidence in the company's future prospects.
One of the primary catalysts driving Moderna's stock rally is the initiation of a mid-stage clinical trial for its experimental cancer vaccine targeting cutaneous squamous cell carcinoma, a prevalent form of skin cancer. This groundbreaking trial, conducted in collaboration with Merck, underscores Moderna's commitment to pioneering innovative solutions in oncology.
In addition to advancements in oncology, Moderna ( NASDAQ:MRNA ) continues to make significant strides in addressing infectious diseases, oncology, and rare diseases. Despite the challenges posed by the endemic market, Moderna ( NASDAQ:MRNA ) reported notable pipeline advancements in its fourth-quarter results. The company anticipates initial regulatory approvals for its RSV vaccine (mRNA-1345) starting in the first half of 2024, further bolstering its position in the market.
Moreover, Moderna ( NASDAQ:MRNA ) remains optimistic about its COVID-19 franchise, projecting profitability in anticipated sales scenarios for 2024 and beyond. With approximately $4 billion in product sales expected in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine, Moderna is poised for robust growth in the coming years.
Technical Analysis
Shares of Moderna ( NASDAQ:MRNA ) is exhibiting a bullish Flag pattern indicating the NASDAQ:MRNA has reacted to the Promising Cancer Vaccine Trials news. With a moderate Relative Strength Index (RSI) of 68.74 NASDAQ:MRNA shares is gaining momentum.
Looking ahead, Moderna's pipeline update revealed a promising outlook, with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Notably, the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 has been fully enrolled, with data expected in 2024. These developments underscore Moderna's commitment to innovation and its potential to deliver groundbreaking therapies to address critical unmet medical needs.
In conclusion, Moderna's recent stock rally reflects growing optimism and confidence in the company's innovative pipeline, particularly in the areas of oncology and infectious diseases. With promising clinical trials underway and a robust portfolio of vaccine candidates, Moderna is well-positioned to capitalize on emerging market opportunities and drive long-term value for investors. As the company continues to make strides in pioneering mRNA technology, investors can expect Moderna to remain at the forefront of medical innovation, potentially revolutionizing the treatment landscape for various diseases, including cancer.
NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings
is coming this upcoming week. This week NVAX news release showed it had settled a years long
litigation over a failed COVID. In the face of earnings around the corner, was this news release
a coincidence or instead a case of excellent executive and legal timing? I will skip the
conspiracy discussion.
On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock
that has been stuck in deeply undervalued territory for a significant time period is remarkable.
I have bought far out of the money call options into 2025 and 2026 some only this past month.
Those from this month are now up over 250% with 11 and 23 months to go to expiration.
I see NVAX as a risky penny medical stock with a high reward potential relative to the
risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is
MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out
the competition when there is an opportunity and do not worry about the government crying
monopoly when life-saving and life-extending medical products are involved. Time will tell.
I expect insane profits.
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is
lurking in the shadows and trying to make a comback. It had an excellent earnings report and
forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored
VWAP and is at the level of the first upper VWAP while in side the high volume area of the
volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing
position here and again the next time I see a dip on the 15-30-minute chart. I look forward
to take a piece out of the position after the next earnings report in about 75 days. I have an
alert for relative volume when the running mean is exceeded on the 30 minute chart which
notify me to take a look at the chart. This is illustrated on this longer time frame chart about
the days around earnings but occurs from time to time from other events. As an aside, if NVAX
gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be
the leading candidate to do a takeover, friendly or otherwise.
NVAX- a medical penny stock Buy Weakness LONGNVAX on a 120 minute chart demonstrates a trend down in the past month after a period of
consolidation producing the POC line on the volume profile. The MACD shows some bullish
divergence. The volume profile has high volume nodes at 4.0 and 5.0 separated by a relative
volume void. NVAX fell quickly through that void. It can just as easily rise through it. See the
linked article on NVA from TipRanks. Options volume and pricing analysis is that bets are looking
at5.0 diligently. Fundamentally, NVAX has been range limited by its focus on COVID but it does
have other projects in its pipeline admittedly on various timelines with varying probabilities
of capitalizing on them depending on clinical trials FDA approvals and so on. On the imbedded
relative strength table as compared with SPY and peers in the pharmaceutical, biotechnology,
medical device and healthcare spaces NVAX compares favorably with MRNA its closest peer
but is weak compared with most of the others I have selected especially with LLY, which is
high-flying from its anti-obesity drug breakout. Device companies Stryker and Intuitive Surgical
are quite strong as well. United Healthcare is dominant in the insurance subsector and strong
overall.
One often effective strategy is to buy when an instrument is oversold and undervalued at a
discount. I will buy NVAX here no matter that I have insider connections with one of those
medical device companies and a few not on the list. Sentiment only goes
so far. I found the article compelling and so Novavax long I go. On a trading site left unsaid
my screenname is "Bottom Feeding Grinder". I have an appetite for NVAX found at the bottom
right now. This is a reversal/reversion to the mean long trade. It is not without risk. As a
penny stock with high volumes, low cost of entry and perhaps low floats, volatility is
underscored and exaggerated if a volume inflow gets underway That said, a short squeeze
is within the spectrum of possibilities. Enough said for now.
Novavax- NVAX- Medical Technology Vaccine Focused LONGNVAX on the 15 minute chart has been compressing price action volatility into a symmetrical
triangle. It in now in a breakout of the triangle and in the process when from undervalued on
Monday to the upper trendline and then down to the support trendline and then up again.
It passed through the volume profile and its high volume area. In short, it has bullish
momentum capped off with a breakout from the high volume area into a bullflag to rest the
weekend. I am in this stock going and now is an opportunity to add to the position. If a trader
wants to know what I consider to be targets upside, let me know. Medical technology is
expected to be among the hottest of subsectors for 2024. NVAX has been beaten down. I
believe it has significant upside for the long term. in the short term, earnings are expected
on February 28th so this is a trade to consider on that run up. Call options for March 2 or March
16 can be considered.
MODERNA BULLISH RUN AHEAD The mRNA stock has exhibited a bullish flag breakout, following the identification of a falling wedge pattern. We anticipate a potential retracement towards the prominent key level near $130, which was established at the top.
Moderna's Surprising Profit Signals Post-Pandemic PivotModerna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause.
Unveiling the Numbers:
Moderna's ( NASDAQ:MRNA ) fourth-quarter profit stood at a commendable $217 million, or 55 cents a share, defying analyst expectations of a substantial loss. This unexpected triumph was fueled by a combination of factors, including unforeseen deferred revenue and a strategic overhaul in manufacturing operations. The company's ability to navigate challenges and adapt swiftly underscores its agility and forward-thinking approach.
Navigating the COVID-19 Landscape:
While Moderna's COVID-19 vaccine continues to be its flagship product, generating substantial revenue, the company is strategically diversifying its portfolio. Despite a decline in COVID vaccine sales from 2022 to 2023, Moderna ( NASDAQ:MRNA ) remains steadfast in its commitment to innovation. The imminent approval decision for its respiratory syncytial virus (RSV) shot marks a significant milestone in this diversification strategy, offering a glimpse into the company's post-pandemic roadmap.
Looking Beyond COVID:
Moderna's ( NASDAQ:MRNA ) ambitious roadmap extends far beyond the realm of COVID-19. With plans to launch its RSV shot in key markets and a robust pipeline of experimental shots targeting influenza, cancer, and cytomegalovirus, the company is poised for a transformative journey. Despite concerns over efficacy declines compared to rival offerings, Moderna's ( NASDAQ:MRNA ) unwavering focus on research and development signals a bold leap into uncharted territories.
International Endeavors:
Moderna's ( NASDAQ:MRNA ) participation in the EU Health Emergency and Response Authority’s tendering procedure underscores its commitment to global health initiatives. By prioritizing key international markets and aligning with strategic partners, the company aims to broaden its reach and impact. The forthcoming decision on the EU tender is poised to shape the company's trajectory in the global arena, setting the stage for future collaborations and expansions.
Charting the Course Ahead:
As Moderna ( NASDAQ:MRNA ) reaffirms its 2024 forecast amidst shifting market dynamics, the company remains steadfast in its pursuit of excellence. With a projected $4 billion in sales and a focus on operational execution, Moderna ( NASDAQ:MRNA ) is poised to navigate challenges and seize opportunities in the years ahead.
Conclusion:
Moderna's ( NASDAQ:MRNA ) unexpected profit surge and strategic roadmap offer a compelling narrative of resilience and innovation in a rapidly evolving landscape. With eyes set on new horizons and a steadfast resolve, Moderna ( NASDAQ:MRNA ) emerges as a beacon of hope in the post-pandemic world.
Moderna's Road to Recovery
Moderna has recently garnered attention for its significant rebound after a challenging 2023. The biotech company, primarily known for its groundbreaking COVID-19 vaccine, is poised for a transformative journey ahead, with a strategic pipeline that extends far beyond pandemic management. This Idea delves into the recent surge in Moderna's stock, the pivotal role of Oppenheimer's upgrade, and the promising prospects that lie ahead.
The Resilience of Moderna Stock:
Following a tumultuous year in 2023, marked by a 45% dip in stock value, Moderna is experiencing a remarkable resurgence. A recent 15% surge was triggered by Oppenheimer's optimistic upgrade to "outperform." The upgrade reflects the financial firm's confidence in Moderna's ability to diversify its product portfolio, projecting the introduction of five new products by 2026. This shift in sentiment underscores the market's recognition of Moderna's potential to pivot beyond its flagship COVID-19 vaccine.
Diversification Beyond COVID-19:
Moderna's dependency on COVID-19 vaccine sales took a toll in 2023, prompting the need for diversification. Oppenheimer analyst Hartaj Singh highlights Moderna's promising pipeline, suggesting the potential launch of several products over the next 12 to 18 months. Among these, an experimental vaccine targeting respiratory syncytial virus (RSV) for older adults stands out, with a potential FDA decision in April 2024. The company's experimental flu vaccine, displaying superior immune response in trials, could also secure approval in 2024 or 2025. Additionally, the prospect of an FDA approval for an experimental personalized cancer vaccine further enhances Moderna's growth potential.
Financial Outlook and Market Response:
Despite a projected dip in COVID-19 vaccine sales in 2024 due to factors like vaccine fatigue, Moderna's overall sales are expected to surge in 2025 and beyond. The company's third-quarter earnings report anticipates revenue to rebound to $4 billion in 2025 after a temporary decline to $4 billion in 2024. Moderna's commitment to launching up to 15 products in the next five years aligns with its goal to diversify revenue streams and minimize reliance on pandemic-related products.
Technical Analysis and Investor Sentiment:
A crucial aspect of Moderna's recent success lies in its positive technical analysis. Breaking the ceiling of the falling trend in the medium-long term signifies a slower rate of decline. While the stock has met the short-term objective at $86.84, the technical indicators suggest cautious optimism. With support at $70.00 and resistance at $118, the stock appears well-positioned for potential growth.
Conclusion
Moderna's stock journey reflects a company resilient in the face of challenges, capitalizing on opportunities beyond the pandemic. Oppenheimer's upgrade and the positive technical analysis signal a turning point for Moderna, with a diversified product portfolio offering a hedge against future uncertainties. As the pharmaceutical giant marches towards its goal of launching innovative products, investors are increasingly viewing Moderna as more than just a COVID-19 play, but a promising player in the broader healthcare landscape.
MRNA Looks ready to roll overModerna has had an astronomical rise due to the vaccine. The technical setup looks excellent to the short side. TD9's on the daily, 2 day, 3 day, big divergences on many timeframes. That said - there is headline risk with this - if they get FDA approval it would likely squeeze.
Moderna’s Stock Boosted by Data From Trial of Melanoma TreatmentModerna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV).
The companies said that after about three years, the combination reduced the risk of recurrence or death by 49% in a Phase 2 trial and the risk of distant metastasis or death by 62%, as compared with Keytruda alone.
“As we continue to follow participants in the Keynote-942/mRNA-4157-P201 study, we are excited to see such a robust clinical benefit with mRNA-4157 (V940) as adjuvant treatment in combination with Keytruda in people with resected high-risk melanoma,” said Kyle Holen, senior vice president and head of development in therapeutics and oncology at Moderna.
“These data add another positive analysis to the multiple endpoints and subgroups previously assessed in this study,” he said.
Technical Analysis
NASDAQ:MRNA reached its 1 Month High on the 14th December, 2023 siting the stocks responds to the Positive Data from the Trial of Melanoma Treatment.
Moderna’s stock has fallen 50% to date in 2023, while the S&P 500 has gained 22.6%.
Although NASDAQ:MRNA is trading near the bottom of its 52-week range and below its 200-day simple moving average, the stock is likewise showing signs of a continual trend which is poise to set foot on a new Resistance level.
Time to buy? First target 35?Its way overbought and numbers looks good. Technically sitting at a good support and can jump anytime. Within 3-5 years, it can give you back 70% gains.
Looking for a bullish reversal on MRNA.
We are in a major daily demand zone here, I will be looking for prices to bounce off of these levels with substantial volume and will hold some long calls. Thank you for partaking of my analysis.
All set to rally towards 160?Its right at the support line and could rally towards 160. It must stay above 95, otherwise its going further down.
Its tech analysis and not any advice to buy/sell.
Moderna Break of Major Support, Short PotentialThis is a Technical Analysis on Moderna (MRNA) on the 1 Week Timeframe.
Current price action shows that we are currently in the process of breaking a MAJOR SUPPORT Zone.
We held critical SUPPORT multiple times ABOVE the $115.00 level, for a span of about 26 months. Expressed by the GREEN circles. But notice we havent been able to successfully rally and stay above the "MAJOR RESISTANCE" line.
Though the CURRENT candle has not yet closed, which it will end of trading session Monday, the 7th of August.
This in my opinion is a critical development. If we CONFIRM below this $115 ish area, the lower range of about $82.00 of the ORANGE zone becomes more likely.
The ORANGE zone, or price range between $115 and $82 has barely any market structure or in other words barely any candles. It would be easy for price to fall stright down, in my opinion.
This can be an area to take a SHORT position.
Another thing to notice since the BLOW of top, we have been forming a DESCENDING TRIANGLE. Its been forming since August 2021, this is NO JOKE. Measuring the target of the end point of descending triangle we get about a 75% drop target. Just remember it doesnt have to play out exactly but its something to consider and keep in the back of the mind.
So just to mention:
1st Target = $82 ish area
2nd Target = $57- $47 range
Last Target = Descending triangle measured target of $29 ( *Less likely for the time being)
RSI has been:
1. printing Lower Highs
2. is currently below the Black Moving average, which i use as an indication of price moving down
3.Is currently in process of ALL TIME RSI LOW, provided we close this weeks candle at current RSI lvl.
STOCH RSI -> Setting up for a BEARish cross. This if it occurs and we are below the MAJOR SUPPORT, bearish momentum can push price down.
Lastly ADX & DI -> We have RED line cross above Green and pointing up. We need to observe this, this indicates also the BEARISH momentum is coming in. If the BLACK moving average curves up and starts moving towards the RED/GREEN line with RED being on top, this will indicate bearish momentum.
CONCLUSION:
We are at major cross roads for MRNA. If we don't have any buying occur during Mondays trading session, and we close below MAJOR SUPPORT, it may be time to SHORT MRNA. We have not had any luck trying to break and stay above the "MAJOR RESISTANCE" line. This, along with multiple touches on MAJOR SUPPORT, has made this WEAK (in my opinion). Short targets include the primary, secondary and descending triangle target levels. Indicators are also shaping up to support the current price action. At times like this, it is important to observe further clues of bearish activity, to be patient and take it one step at a time.
Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again.
If you have any questions, do reach out. Thank you again.
DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. When trading always spend majority of your time on risk management strategy.
Covid 2023 - Profiting from CorruptionHello everyone Josh here again. I’m sure by now you’ve already heard mumblings of Covid’s imminent return. We are seeing everything from colleges to hospitals start to implement Covid policies. The news cycle is starting to warn of a dangerous flu season/Covid return. Governments around the world are now updating their Covid policies and sleepy Joe’s White House is still pushing for the mass vaccination and experimentation on of human guinea pigs around the world.
With all this being said, it is my idea that we are about to go back into lockdown/full Covid policy mode. Although I wish this was not the case, I do intend to profit from it.
Illustrated is the Moderna chart, I use this, as it was one of the first assets I made money off of during the last pandemic, in fact, you can still go back and see my old idea on my page about Moderna when I called it at around sub $60. However, this could’ve been any chart from Amazon and Netflix to hospital sectors, to e-commerce platforms like Shopify. Basically, anything that will go up during a full-scale, pandemic/lockdown.
If my gut feeling is right, and we are going to go into a full-scale lock down, it might be one of the easiest plays of the century.
During the last pandemic, we saw airlines, cruise lines, casinos and resorts and a myriad of other sectors collapse to unprecedented lows. I expect something similar to happen this time around, to varying degrees of severity. Many people made millions by shorting assets last pandemic, I think we are setting ourselves up for the perfect storm to profit.
Look for stocks to long and short. Ignore the noise and make your money off of the lies of the global elite.
Below is an AI rendered breakdown of this idea.
Thank you so much for reading.
Please follow and like my ideas :)
Investment Thesis: Navigating Pandemic-Related Market Trends
I. Introduction:
The investment thesis centers around capitalizing on potential market shifts resulting from pandemic-related policies enacted by governments and corporations globally.
II. Market Outlook:
Anticipating the implementation of pandemic-related rules and regulations, which could include mask mandates, lockdowns, and travel restrictions.
III. Asset Allocation Strategy:
A. Long Positions:
E-commerce Dominance: As witnessed during the previous pandemic, e-commerce platforms like Amazon thrived. This trend is likely to persist as people turn to online shopping for convenience and safety.
Entertainment Streaming: Companies like Netflix benefited from increased demand for home entertainment. Expect this trend to continue, making streaming platforms potentially profitable investments.
Pharmaceutical Giants: Pfizer and Moderna played pivotal roles in vaccine development during the Covid pandemic. Their expertise positions them well for potential future vaccine requirements or pharmaceutical innovations.
Healthcare Stocks: Hospital and healthcare-related stocks may experience increased demand as health services remain crucial during pandemic periods.
B. Short Positions:
Travel and Hospitality Sectors: Historical data shows that airlines, cruise liners, resorts, and casinos experienced significant declines during the last pandemic due to travel restrictions and reduced consumer spending.
IV. Risk Considerations:
While historical patterns suggest certain sectors will benefit and others may decline during pandemics, unforeseen variables can impact market dynamics. Careful monitoring and adaptability are essential.
V. Diversification and Hedging:
To mitigate risks, consider diversifying your portfolio across industries and asset types. This approach helps balance potential losses from short positions with gains from long positions.
VI. Exit Strategy:
Regularly reassess the investment landscape, keeping an eye on shifts in policies, vaccination rates, and economic indicators. Be prepared to adjust your positions accordingly to optimize gains or minimize losses.
VII. Conclusion:
In light of potential pandemic-related policies, a strategic investment approach involves capitalizing on e-commerce, streaming, pharmaceutical, and healthcare sectors, while shorting travel and hospitality sectors. Prudent risk management, diversification, and a proactive exit strategy will be pivotal in navigating the ever-evolving market landscape.
Please note that investment decisions involve inherent risks, and it's advisable to consult with a qualified financial advisor before executing any investment strategy.
